0.10 11/16 2.50 Calls

Earnings on 11/08 with a new License agreement (1), changes in the board (2), and put to call ratio 0.19 (3), will be looking to exit if the price drops below 2. Entered position due to earnings and oversold conditions, will hold position if a positive change in momentum occurs, with a break in daily resistance and positive Stoch .

1: "BOSTON and GERMANTOWN, Md ., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (NASDAQ:ZIOP) and Precigen , Inc. , a wholly-owned subsidiary of Intrexon Corporation (NASDAQ:XON), today announced a new definitive license agreement to replace all existing agreements between the companies that will provide Ziopharm with certain exclusive and non-exclusive rights to technology controlled by Precigen , Inc.

Through the new agreement, Ziopharm will primarily focus its resources on developing its Controlled IL-12 and Sleeping Beauty ( SB ) T-cell receptor ( TCR ) platform technologies which have the capability to treat solid tumors, while Intrexon further establishes Precigen as a therapeutics company concentrating on immuno-oncology, autoimmune and infectious disease therapies. Both companies will be better positioned to independently focus on their respective platforms and markets with full developmental and financial controls." ZIOP /

2:OSTON, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (NASDAQ:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced changes to its Board of Directors and management team. Ziopharm's Chief Executive Officer Laurence Cooper, M.D., Ph .D, is appointed to the Board of Directors effective immediately, and Francois Lebel, M.D., is stepping down from his position as Chief Medical Officer (CMO) and Executive Vice President of Research & Development, effective Oct. 26.

"We are pleased to continue the evolution of the Board of Directors with the addition of Dr . Cooper as the Company's CEO," said Ziopharm's Lead Director Scott Tarriff, who is Chief Executive Officer of Eagle Pharmaceuticals . "We support Laurence and his plan for the Company's management team to advance the Controlled IL-12 and Sleeping Beauty platforms." ZIOP /

Comment: Potential short squeeze Days to Cover 24 with short to float percent at 29. Still holding since close below 2 has not occurred.
Comment: Entered long position 1.98 stop loss at low of 1.90
Comment: Exited at 0.15